SWOG clinical trial number
S1826
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL
Status Notes
Permanently closed to accrual, effective December 01, 2022, 12:00 p.m. Pacific Time
Activated
07/19/2019
Closed
12/01/2022
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lymphoma
Treatment
Doxorubicin
Filgrastim
Vinblastine Sulfate
Radiation Therapy
Pegfilgrastim
Nivolumab
Brentuximab Vedotin
Dacarbazine
RT
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
8% Accrual
Accrual
8%
Open
Phase
S2207
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase